A Small Pregnancy Study Linked Blood and Uterine Aging-Clock Signals

In 2022, researchers published “Advancing understanding of maternal age: correlating epigenetic clocks in blood and myometrium” in Epigenetics Communications. October 2026 coverage revisited the study’s comparison of DNA-methylation clocks in matched blood and uterine tissue collected around delivery.

GrimAge showed the strongest cross-tissue relationship

The study found that Horvath, Hannum and GrimAge estimates correlated significantly with chronological age in both blood and uterine myometrium. GrimAge showed the strongest reported relationship between age estimates from the two tissues. The researchers proposed that maternal blood epigenetic age might serve as a proxy for myometrial epigenetic age. For healthy-aging research, the contribution is an early demonstration of how age-related signals compare across tissues rather than a finding about extending healthy life.

The evidence came from matched human samples

This was an observational study in humans, using matched blood and uterine tissue samples rather than animal models or an in vitro intervention.

According to the study coverage, researchers began with samples from 27 pregnant participants scheduled for term cesarean births. After quality control, they analyzed 21 matched blood and myometrium samples. Participants were 20 to 50 years old with a median age of 35.5 years.

Blood was collected before delivery. Myometrial tissue was collected during cesarean birth. This paired design allowed researchers to compare measurements from the same participants rather than compare blood from one group with uterine tissue from another.

The team measured DNA methylation across more than 850,000 CpG sites. It then calculated age estimates using Horvath, Hannum, PhenoAge and GrimAge. Applying several clocks to the samples made it possible to examine whether the choice of model changed the result.

The sampling design is the study’s central strength. A proposed blood marker of another tissue needs a comparison with that tissue rather than an assumption that the signals match. Here, the researchers had both measurements available within each matched sample set.

Chronological age and cross-tissue correspondence are different tests

The first comparison asked whether a clock’s estimate rose with participants’ chronological age. For the three clocks that significantly tracked age in both tissues, correlations ranged from 0.72 to 0.87 in blood. In myometrium, the reported range was 0.62 to 0.70. These figures describe relationships across participants rather than the proportion of samples assigned the correct age.

The second comparison asked whether blood and uterine estimates moved together within the matched sample. GrimAge had the strongest reported correspondence. That finding supported the researchers’ proposal to investigate blood as a possible proxy for myometrial epigenetic age.

These comparisons answer different questions. A clock can track chronological age in blood while its relationship with another tissue still requires separate evaluation. The paired samples made that second evaluation possible in this study.

A further analysis considered age acceleration, meaning the clock estimate adjusted for chronological age. The reported cross-tissue correlation for GrimAge age acceleration was 0.49. This adjustment asks about the signal beyond calendar age rather than simply whether older participants receive older clock estimates.

Keeping these analyses separate helps clarify the finding. Tracking chronological age addresses one aspect of a clock’s behavior. Comparing adjusted estimates across tissues addresses another. Neither comparison should be substituted for the other when describing the research.

A clock’s purpose shapes its interpretation

Stanford Medicine’s overview of biological age explains that clocks differ in what they were designed to estimate. That makes the choice of clock model central to interpreting this experiment. The question is not simply which model returns an age number. It is which measurement fits the tissue and research question being examined.

In the uterine study, the researchers examined chronological-age relationships and correspondence between tissues. Those are useful early questions for developing a biomarker. They establish what was compared and provide a starting point for deciding what a later validation study should test.

This distinction also gives the result a specific place within longevity science. The study concerns the interpretation of biological-age measurements in a particular reproductive setting. Its immediate contribution is methodological: it provides paired human observations that future research can try to reproduce and connect with function.

Several limits keep the finding at proof of concept

The study coverage identifies important constraints on both the measurements and their interpretation:

• The sample was small and narrowly selected. The cohort was overwhelmingly white/European and included only planned term cesarean births. It did not include participants who labored. The results therefore need testing in larger and more representative populations before their relevance to pregnancy more broadly can be assessed.
• Clinical prediction and uterine function were not tested. The study did not evaluate prediction of prolonged labor or labor dysfunction. It also did not test postpartum hemorrhage, preeclampsia or other pregnancy outcomes. No contraction testing was performed on the preserved tissue. The observed correlations therefore do not establish clinical pregnancy-risk prediction.
• The clocks produced substantially different absolute ages. Horvath estimated a median myometrial age of 49.4 years. Hannum and GrimAge estimated medians of 19.7 and 32.7 years respectively. Horvath placed every myometrial sample at age 40 or older despite participants spanning ages 20 to 50. These differences argue against treating any single output as a definitive uterine age.
• PhenoAge did not significantly track chronological age in myometrium. The result shows that the observed relationships were not shared by every model tested. It supports evaluating each clock in the intended tissue rather than treating the clocks as interchangeable measures.
• Potential confounders were incompletely assessed. The investigators had limited clinical information available for examining other influences on the results. The report also notes that pregnancy-related hormonal and immune changes may affect methylation patterns. Clocks developed in other contexts were not necessarily designed to capture those changes.
• The BMI association did not survive statistical correction. Myometrial GrimAge acceleration correlated with pre-pregnancy BMI at 0.52 before correction. The association was no longer significant after correction for multiple testing. It should remain a preliminary observation rather than evidence that higher BMI accelerates uterine aging.
• The reported cross-tissue values were not fully consistent. For GrimAge’s blood-to-myometrium age correlation, the abstract reported 0.80 while the results narrative reported 0.81. That reporting difference should remain visible instead of being replaced with a single supposedly exact value.
• Blood is an indirect measurement of another tissue. Stanford Medicine’s overview cautions that clock results contain measurement error and that blood measurements cannot directly reveal how other organs are aging. The matched comparison is therefore a validation step to investigate further rather than permission to interpret blood as a universal organ-age test.

For readers assessing biological-age testing, a useful sequence is to identify the sampled tissue and the purpose of the clock. Then distinguish a relationship with chronological age from evidence about function or future health outcomes. A result expressed in years still needs a biological interpretation, as discussed in this guide to reading DNA-methylation measurements. Personal questions about pregnancy risk or testing belong with a qualified maternity-care professional.

Validation must connect the signal with pregnancy outcomes

The next step is replication in larger and more representative pregnancy cohorts, followed by testing whether blood-based clock signals predict uterine function or meaningful pregnancy outcomes beyond chronological age.

How AgeAmaze helps

Pregnancy biomarker claims put the evidence reviewer on a reader’s team in charge of separating experimental measurements from health claims, and AgeAmaze brings research-led explanations to that task. Its coverage addresses overstated biological-age claims by giving research-minded adults context for judging established findings alongside promising or speculative ideas.

Read the research

Sources

1. med.stanford.edu · news · insightsBiological age versus chronological age: What the science says
2. Epigenetic clocks reveal how the aging uterus ticks during ...